This o2h ChaiTime is on Using Knowledge Intensive Investing to spur the growth of UK Biotech therapeutics to generate returns (financial, social and ethical) for investors as part of the Seed and early finance cycle.
Following his training at the University of Glasgow Dr Andrew joined the biotech BioFocus, working on a range of drug discovery targets and designed cutting edge product lines such as DGF-out kinase inhibitors, ion channel modulators and fragment libraries.
Martin’s career in the City started as a healthcare analyst in 1987, working at Morgan Grenfell and then UBS. He joined HSBC in 1992, where he was Head of Global Pharmaceutical/Healthcare Equity Research.
Mark has over twenty years experience in Financial services and prior to becoming Director General of the EIS Association, he was Head of Research and Development at Mazars, a leading UK financial planning firm.